Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study.

被引：0
|
作者：
Moinpour, C
Wu, J
Donaldson, G
Liepa, A
Melemed, A
Oshaughnessy, J
Rappold, E
Albain, K
机构：
[1] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Utah, Salt Lake City, UT 84112 USA
[4] US Oncol Res Inc, Dallas, TX USA
[5] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
621
引用
收藏
页码：32S / 32S
页数：1
相关论文
共 50 条
  • [1] Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer.
    Llombart, Antonio
    Espie, Marc
    Ranade, Anantbhushan
    Trukhin, Dmytro
    Hegg, Roberto
    Del Giglio, Auro
    Paridaens, Robert
    Staroslawska, Elzbieta
    Veyret, Corinne
    Sakaeva, Dina
    Gomez, Henry Leonidas
    Lokanatha, Dasappa
    Lerzo, Guillermo Luis
    Shewalkar, Balaji Keshavrao
    Talbot, Denis Charles
    Santoro, Armando
    Roche, Henri Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival
    Albain, KS
    Nag, S
    Calderillo-Ruiz, G
    Jordaan, JP
    Llombart, A
    Pluzanska, A
    Pawlicki, M
    Melemed, AS
    O'Shaughnessy, J
    Reyes, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [3] Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB2+ patients -: Quality of Life (QOL) results
    Wu, Y.
    Segreti, A.
    Cella, D.
    DiLeo, A.
    Amonkar, M.
    Koehler, M.
    Arbushites, M.
    Walkers, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 171 - 171
  • [4] Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment.
    Del Mastro, Lucia
    Fabi, Alessandra
    Mansutti, Mauro
    De Laurentiis, Michele
    Durando, Antonio
    Colantuoni, Giuseppe
    Zaniboni, Alberto
    Barni, Sandro
    Merlo, Domenico Franco
    Bruzzi, Paolo
    La Torre, Ignazia
    Ceccarelli, Matteo
    Kazeem, Gbenga
    Marchi, Paolo
    Boy, Davide
    Venturini, Marco
    De Placido, Sabino
    Cognetti, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Hao, Chunfang
    He, Lihong
    Dong, Guolei
    Wang, Xiaorui
    Jia, Yongsheng
    Zhang, Li
    CANCER RESEARCH, 2015, 75
  • [7] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
  • [8] Results of first-line weekly paclitaxel (P) plus gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
    Mousseau, M.
    Serin, D.
    Petit, T.
    Priou, F.
    Zelek, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
12345